Dabigatran benefits outweigh risks, TGA review finds

In a statement for prescribers posted on its website on Friday, the regulator emphasised the importance of patient selection.

“Prescribers are urged to give careful consideration to the suitability of their patients for dabigatran, particularly with regard to the risks of bleeding and their current stability on warfarin or other anticoagulants,” it said.

Manufacturer Boehringer Ingelheim said today the outcome was in line with reviews